Safety of long-term treatment of HAM/TSP patients with valproic acid.

@article{Olindo2011SafetyOL,
  title={Safety of long-term treatment of HAM/TSP patients with valproic acid.},
  author={Stephane Olindo and Gildas Belrose and Nicolas Gillet and Sabrina Men{\'e}ndez Rodr{\'i}guez and Mathieu Boxus and Olivier Verlaeten and Becca Asquith and Charles R. M. Bangham and A{\"i}ssatou Signat{\'e} and Didier Smadja and Agn{\`e}s L{\'e}zin and Raymond C{\'e}saire and Lucas Willems},
  journal={Blood},
  year={2011},
  volume={118 24},
  pages={
          6306-9
        }
}
HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a neurodegenerative disease of the central nervous system induced by human T-lymphotropic virus type 1. As a potential therapeutic approach, we previously suggested reducing the proviral load by modulating lysine deacetylase activity using valproic acid (VPA) and exposing virus-positive cells to the host immune response. We conducted a single-center, 2-year, open-label trial, with 19 HAM/TSP volunteers treated with oral VPA… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 32 CITATIONS

Rates of CTL Killing in Persistent Viral Infection In Vivo

  • PLoS Computational Biology
  • 2014
VIEW 3 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 12 REFERENCES

Similar Papers

Loading similar papers…